Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Morgan Stanley began coverage on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research report released on ...
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results